XOMA (XOMA) – Globe Newswire
-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
-
XOMA Corporation Announces Closing of Tender Offer
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
-
XOMA to Present at Upcoming Investor Conferences in March
-
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
-
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
-
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
-
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
-
XOMA Announces Stock Repurchase Program of up to $50 Million
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
-
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
-
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
-
XOMA Added to the Russell 2000® and Russell 3000® Indexes
-
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
-
XOMA to Present at H.C. Wainwright BioConnect Investor Conference
-
XOMA to Present at H.C. Wainwright BioConnect Investor Conference
-
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
-
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
-
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
-
XOMA to Present at 43rd Annual Cowen Health Care Conference
-
XOMA to Present at 43rd Annual Cowen Health Care Conference
-
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
-
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
-
XOMA Declares Quarterly Preferred Stock Dividends
-
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
-
XOMA to Present at H.C. Wainwright Global Investment Conference
-
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference
-
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events
-
XOMA to Present at the 42nd Annual Cowen Health Care Conference
-
XOMA to Present at Aegis Capital Corp Investor Conference
-
XOMA Declares Quarterly Preferred Stock Dividends
-
XOMA to Present at Upcoming Investor Conferences
Back to XOMA Stock Lookup